Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 19/20 | 0.62 |
| ▸ | PRAP1 | Q96NZ9 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14028998 | 1.00 | PARP1 (0.62) | PARP1PRAP1CYP3A4CYP2C9TSHR | |
| SCHEMBL4088922 | 0.89 | PARP1 (0.59) | PARP1PRAP1 | |
| SCHEMBL14029001 | 0.88 | PARP1 (0.61) | PARP1 | |
| SCHEMBL3630956 | 0.88 | PARP1 (0.61) | PARP1 | |
| SCHEMBL1801940 | 0.88 | PARP1 (0.58) | PARP1PRAP1CYP3A4CYP2C9TSHR | |
| Hydrochloric Acid SCHEMBL3636680 | 0.87 | PARP1 (0.60) | PARP1 | |
| SCHEMBL4104414 | 0.87 | PARP1 (0.57) | PARP1PRAP1 | |
| SCHEMBL14028997 | 0.87 | PARP1 (0.57) | PARP1PRAP1CYP3A4CYP2C9TSHR | |
| SCHEMBL3634804 | 0.87 | PARP1 (0.57) | PARP1PRAP1CYP3A4CYP2C9TSHR | |
| SCHEMBL4094897 | 0.86 | PARP1 (0.56) | PARP1PRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155726-A1 | PHTHALAZINONE DERIVATIVES AND THEIR USE AS MEDICAMENT TO TREAT CANCER | Kudos Pharmaceuticals Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| US-20080255128-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| WO-2008122810-A1 | PHTHALAZINONE DERIVATIVES AND THEIR USE AS MEDICAMENT TO TREAT CANCER | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255128-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | PARP1, PARP11, PARP2 | PARP1 1/4885PRAP1 1153/4885CYP3A4 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.